Law ❯ Litigation ❯ Class Action ❯ Shareholder Rights

Securities Fraud

ImmunityBio Investors Face May 26 Deadline to Seek Lead Role in Securities Case

The case stems from an FDA warning that ImmunityBio's Anktiva ads made unsupported cure claims.

Tesla Appeals $243 Million Autopilot Verdict and Battles Shareholders’ Robotaxi Suit